nodes	percent_of_prediction	percent_of_DWPC	metapath
Glycine—AGXT2—Pyrimidine catabolism—NT5C3A—bone cancer	0.0549	0.0788	CbGpPWpGaD
Glycine—BAAT—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.0323	0.0464	CbGpPWpGaD
Glycine—AGXT2—Pyrimidine metabolism—NT5C3A—bone cancer	0.0315	0.0453	CbGpPWpGaD
Glycine—SHMT2—Folate Metabolism—FOLR1—bone cancer	0.0287	0.0413	CbGpPWpGaD
Glycine—SHMT1—Metabolism of folate and pterines—DHFR—bone cancer	0.0229	0.0329	CbGpPWpGaD
Glycine—Fluid overload—Carboplatin—bone cancer	0.0209	0.14	CcSEcCtD
Glycine—BAAT—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.0189	0.0271	CbGpPWpGaD
Glycine—BAAT—Farnesoid X Receptor  Pathway—CYP3A4—bone cancer	0.0173	0.0248	CbGpPWpGaD
Glycine—SHMT1—Folate Metabolism—FOLR1—bone cancer	0.0169	0.0243	CbGpPWpGaD
Glycine—SHMT2—One Carbon Metabolism—DHFR—bone cancer	0.0157	0.0225	CbGpPWpGaD
Glycine—GLYATL1—Metapathway biotransformation—CYP4V2—bone cancer	0.0155	0.0222	CbGpPWpGaD
Glycine—GLYAT—Metapathway biotransformation—CYP4V2—bone cancer	0.0155	0.0222	CbGpPWpGaD
Glycine—GLYATL2—Metapathway biotransformation—CYP4V2—bone cancer	0.0155	0.0222	CbGpPWpGaD
Glycine—BAAT—Metapathway biotransformation—CYP4V2—bone cancer	0.0148	0.0212	CbGpPWpGaD
Glycine—SHMT2—Trans-sulfuration and one carbon metabolism—DHFR—bone cancer	0.0141	0.0202	CbGpPWpGaD
Glycine—Diuresis—Cisplatin—bone cancer	0.0123	0.0824	CcSEcCtD
Glycine—AGXT2—Nucleotide metabolism—NT5C3A—bone cancer	0.0123	0.0176	CbGpPWpGaD
Glycine—Blindness transient—Methotrexate—bone cancer	0.0115	0.0767	CcSEcCtD
Glycine—SLC6A5—spinal cord—bone cancer	0.0102	0.0665	CbGeAlD
Glycine—ALAS1—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.00982	0.0141	CbGpPWpGaD
Glycine—GRIN2C—Hypothetical Network for Drug Addiction—GRM1—bone cancer	0.00944	0.0136	CbGpPWpGaD
Glycine—SHMT1—One Carbon Metabolism—DHFR—bone cancer	0.00923	0.0133	CbGpPWpGaD
Glycine—GSS—Metapathway biotransformation—CYP4V2—bone cancer	0.00889	0.0128	CbGpPWpGaD
Glycine—GPR18—GPCRs, Other—GRM1—bone cancer	0.00885	0.0127	CbGpPWpGaD
Glycine—GLYATL2—bone marrow—bone cancer	0.00875	0.0568	CbGeAlD
Glycine—SHMT1—Trans-sulfuration and one carbon metabolism—DHFR—bone cancer	0.00829	0.0119	CbGpPWpGaD
Glycine—GSS—Trans-sulfuration and one carbon metabolism—DHFR—bone cancer	0.00808	0.0116	CbGpPWpGaD
Glycine—SLC32A1—spinal cord—bone cancer	0.00804	0.0522	CbGeAlD
Glycine—SHMT2—Folate Metabolism—DHFR—bone cancer	0.00789	0.0113	CbGpPWpGaD
Glycine—SLC6A9—spinal cord—bone cancer	0.00776	0.0504	CbGeAlD
Glycine—SHMT1—Validated targets of C-MYC transcriptional activation—BMI1—bone cancer	0.0077	0.0111	CbGpPWpGaD
Glycine—ALAS2—bone marrow—bone cancer	0.00733	0.0476	CbGeAlD
Glycine—GRIN2A—Hypothetical Network for Drug Addiction—GRM1—bone cancer	0.00721	0.0103	CbGpPWpGaD
Glycine—GPR18—tendon—bone cancer	0.007	0.0455	CbGeAlD
Glycine—GPR18—bone marrow—bone cancer	0.00678	0.044	CbGeAlD
Glycine—GPR18—GPCRs, Other—SMO—bone cancer	0.00623	0.00895	CbGpPWpGaD
Glycine—Fluid overload—Cisplatin—bone cancer	0.00614	0.0411	CcSEcCtD
Glycine—GSS—Glutathione conjugation—GSTP1—bone cancer	0.00586	0.00841	CbGpPWpGaD
Glycine—GARS—connective tissue—bone cancer	0.00572	0.0371	CbGeAlD
Glycine—GLDC—spinal cord—bone cancer	0.00524	0.034	CbGeAlD
Glycine—PIPOX—tendon—bone cancer	0.00508	0.033	CbGeAlD
Glycine—GCAT—tendon—bone cancer	0.00492	0.032	CbGeAlD
Glycine—PIPOX—spinal cord—bone cancer	0.0049	0.0318	CbGeAlD
Glycine—GPR18—G alpha (i) signalling events—GRM4—bone cancer	0.00478	0.00686	CbGpPWpGaD
Glycine—GPR18—G alpha (i) signalling events—RGS1—bone cancer	0.00478	0.00686	CbGpPWpGaD
Glycine—GCAT—bone marrow—bone cancer	0.00477	0.031	CbGeAlD
Glycine—GCAT—spinal cord—bone cancer	0.00475	0.0308	CbGeAlD
Glycine—SHMT1—Folate Metabolism—DHFR—bone cancer	0.00465	0.00667	CbGpPWpGaD
Glycine—GARS—Gene Expression—ZNF77—bone cancer	0.00456	0.00654	CbGpPWpGaD
Glycine—GLYATL2—Phase II conjugation—GSTP1—bone cancer	0.00454	0.00652	CbGpPWpGaD
Glycine—GLYAT—Phase II conjugation—GSTP1—bone cancer	0.00454	0.00652	CbGpPWpGaD
Glycine—GLYATL1—Phase II conjugation—GSTP1—bone cancer	0.00454	0.00652	CbGpPWpGaD
Glycine—ALAS1—tendon—bone cancer	0.00432	0.028	CbGeAlD
Glycine—SHMT1—Validated targets of C-MYC transcriptional activation—EIF2S1—bone cancer	0.00431	0.00619	CbGpPWpGaD
Glycine—ALAS1—bone marrow—bone cancer	0.00418	0.0271	CbGeAlD
Glycine—ALAS1—spinal cord—bone cancer	0.00416	0.027	CbGeAlD
Glycine—Pain—Carboplatin—bone cancer	0.00397	0.0266	CcSEcCtD
Glycine—GARS—tendon—bone cancer	0.00393	0.0255	CbGeAlD
Glycine—GARS—bone marrow—bone cancer	0.00381	0.0247	CbGeAlD
Glycine—GARS—spinal cord—bone cancer	0.00379	0.0246	CbGeAlD
Glycine—SHMT1—Defective AMN causes hereditary megaloblastic anemia 1—DHFR—bone cancer	0.00373	0.00535	CbGpPWpGaD
Glycine—GATM—spinal cord—bone cancer	0.0036	0.0234	CbGeAlD
Glycine—SHMT2—tendon—bone cancer	0.00342	0.0222	CbGeAlD
Glycine—SLC6A5—NRF2 pathway—GSTP1—bone cancer	0.0034	0.00488	CbGpPWpGaD
Glycine—SLC6A9—NRF2 pathway—GSTP1—bone cancer	0.0034	0.00488	CbGpPWpGaD
Glycine—SLC6A5—NRF2 pathway—TGFBR2—bone cancer	0.0034	0.00488	CbGpPWpGaD
Glycine—SLC6A9—NRF2 pathway—TGFBR2—bone cancer	0.0034	0.00488	CbGpPWpGaD
Glycine—SHMT2—bone marrow—bone cancer	0.00331	0.0215	CbGeAlD
Glycine—GRIN2C—CREB phosphorylation through the activation of Ras—BRAF—bone cancer	0.00327	0.0047	CbGpPWpGaD
Glycine—Encephalopathy—Methotrexate—bone cancer	0.00326	0.0218	CcSEcCtD
Glycine—Polyuria—Cisplatin—bone cancer	0.00316	0.0211	CcSEcCtD
Glycine—SHMT1—tendon—bone cancer	0.00311	0.0202	CbGeAlD
Glycine—GLYATL2—Biological oxidations—CYP3A4—bone cancer	0.00311	0.00446	CbGpPWpGaD
Glycine—GLYATL1—Biological oxidations—CYP3A4—bone cancer	0.00311	0.00446	CbGpPWpGaD
Glycine—GLYAT—Biological oxidations—CYP3A4—bone cancer	0.00311	0.00446	CbGpPWpGaD
Glycine—GLRB—spinal cord—bone cancer	0.00309	0.0201	CbGeAlD
Glycine—GLYAT—Metapathway biotransformation—CYP3A4—bone cancer	0.00306	0.0044	CbGpPWpGaD
Glycine—GLYATL2—Metapathway biotransformation—CYP3A4—bone cancer	0.00306	0.0044	CbGpPWpGaD
Glycine—GLYATL1—Metapathway biotransformation—CYP3A4—bone cancer	0.00306	0.0044	CbGpPWpGaD
Glycine—SHMT1—bone marrow—bone cancer	0.00302	0.0196	CbGeAlD
Glycine—Lung disorder—Methotrexate—bone cancer	0.00296	0.0198	CcSEcCtD
Glycine—BAAT—Metapathway biotransformation—CYP3A4—bone cancer	0.00292	0.0042	CbGpPWpGaD
Glycine—GPR18—GPCR ligand binding—GRM4—bone cancer	0.00289	0.00415	CbGpPWpGaD
Glycine—Hyponatraemia—Cisplatin—bone cancer	0.00278	0.0186	CcSEcCtD
Glycine—Lung disorder—Epirubicin—bone cancer	0.00277	0.0185	CcSEcCtD
Glycine—GRIN2C—Post NMDA receptor activation events—BRAF—bone cancer	0.00269	0.00387	CbGpPWpGaD
Glycine—GRIN2A—tendon—bone cancer	0.00267	0.0173	CbGeAlD
Glycine—SLC6A5—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.00267	0.00384	CbGpPWpGaD
Glycine—SLC6A9—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.00267	0.00384	CbGpPWpGaD
Glycine—GLYATL2—Biological oxidations—GSTP1—bone cancer	0.00266	0.00381	CbGpPWpGaD
Glycine—GLYAT—Biological oxidations—GSTP1—bone cancer	0.00266	0.00381	CbGpPWpGaD
Glycine—GLYATL1—Biological oxidations—GSTP1—bone cancer	0.00266	0.00381	CbGpPWpGaD
Glycine—SLC36A1—tendon—bone cancer	0.00266	0.0172	CbGeAlD
Glycine—GLYATL1—Metapathway biotransformation—GSTP1—bone cancer	0.00262	0.00376	CbGpPWpGaD
Glycine—GLYATL2—Metapathway biotransformation—GSTP1—bone cancer	0.00262	0.00376	CbGpPWpGaD
Glycine—GLYAT—Metapathway biotransformation—GSTP1—bone cancer	0.00262	0.00376	CbGpPWpGaD
Glycine—GSS—Phase II conjugation—GSTP1—bone cancer	0.00261	0.00374	CbGpPWpGaD
Glycine—GRIN2A—spinal cord—bone cancer	0.00258	0.0167	CbGeAlD
Glycine—Dehydration—Cisplatin—bone cancer	0.00258	0.0172	CcSEcCtD
Glycine—SLC36A1—bone marrow—bone cancer	0.00257	0.0167	CbGeAlD
Glycine—Lung disorder—Doxorubicin—bone cancer	0.00256	0.0171	CcSEcCtD
Glycine—GPR18—GPCR ligand binding—GRM1—bone cancer	0.00251	0.0036	CbGpPWpGaD
Glycine—BAAT—Metapathway biotransformation—GSTP1—bone cancer	0.0025	0.00359	CbGpPWpGaD
Glycine—GRIN2A—CREB phosphorylation through the activation of Ras—BRAF—bone cancer	0.0025	0.00359	CbGpPWpGaD
Glycine—GRIN2C—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—bone cancer	0.00248	0.00356	CbGpPWpGaD
Glycine—ALAS2—Metabolism—NDUFA12—bone cancer	0.00246	0.00353	CbGpPWpGaD
Glycine—GSS—tendon—bone cancer	0.00234	0.0152	CbGeAlD
Glycine—SLC6A5—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.00231	0.00331	CbGpPWpGaD
Glycine—SLC6A9—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.00231	0.00331	CbGpPWpGaD
Glycine—GLRA2—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.00227	0.00326	CbGpPWpGaD
Glycine—SLC32A1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.00227	0.00326	CbGpPWpGaD
Glycine—GLRA3—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.00227	0.00326	CbGpPWpGaD
Glycine—GSS—bone marrow—bone cancer	0.00226	0.0147	CbGeAlD
Glycine—GSS—spinal cord—bone cancer	0.00225	0.0146	CbGeAlD
Glycine—Cardiovascular disorder—Epirubicin—bone cancer	0.00223	0.0149	CcSEcCtD
Glycine—GARS—Gene Expression—FUS—bone cancer	0.00223	0.0032	CbGpPWpGaD
Glycine—SHMT1—Validated targets of C-MYC transcriptional activation—CDK4—bone cancer	0.00211	0.00304	CbGpPWpGaD
Glycine—Cardiovascular disorder—Doxorubicin—bone cancer	0.00206	0.0138	CcSEcCtD
Glycine—GRIN2A—Post NMDA receptor activation events—BRAF—bone cancer	0.00206	0.00295	CbGpPWpGaD
Glycine—ALAS2—Metabolism—NT5C3A—bone cancer	0.00204	0.00292	CbGpPWpGaD
Glycine—GLRA3—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.00196	0.00282	CbGpPWpGaD
Glycine—GLRA2—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.00196	0.00282	CbGpPWpGaD
Glycine—SLC32A1—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.00196	0.00282	CbGpPWpGaD
Glycine—Coma—Methotrexate—bone cancer	0.00191	0.0128	CcSEcCtD
Glycine—Salivary hypersecretion—Epirubicin—bone cancer	0.0019	0.0127	CcSEcCtD
Glycine—GRIN2A—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—bone cancer	0.00189	0.00272	CbGpPWpGaD
Glycine—GLYATL2—Metabolism—NDUFA12—bone cancer	0.00186	0.00267	CbGpPWpGaD
Glycine—GLYAT—Metabolism—NDUFA12—bone cancer	0.00186	0.00267	CbGpPWpGaD
Glycine—GLYATL1—Metabolism—NDUFA12—bone cancer	0.00186	0.00267	CbGpPWpGaD
Glycine—GATM—Metabolism—NDUFA12—bone cancer	0.00186	0.00267	CbGpPWpGaD
Glycine—GLRB—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.00185	0.00266	CbGpPWpGaD
Glycine—Visual impairment—Cisplatin—bone cancer	0.00185	0.0124	CcSEcCtD
Glycine—Coma—Epirubicin—bone cancer	0.00179	0.012	CcSEcCtD
Glycine—GSS—Biological oxidations—CYP3A4—bone cancer	0.00178	0.00256	CbGpPWpGaD
Glycine—BAAT—Metabolism—NDUFA12—bone cancer	0.00178	0.00255	CbGpPWpGaD
Glycine—GPR18—GPCR ligand binding—SMO—bone cancer	0.00177	0.00254	CbGpPWpGaD
Glycine—SHMT2—Folate Metabolism—TP53—bone cancer	0.00176	0.00253	CbGpPWpGaD
Glycine—Salivary hypersecretion—Doxorubicin—bone cancer	0.00176	0.0118	CcSEcCtD
Glycine—GSS—Metapathway biotransformation—CYP3A4—bone cancer	0.00176	0.00253	CbGpPWpGaD
Glycine—Thrombophlebitis—Methotrexate—bone cancer	0.00176	0.0118	CcSEcCtD
Glycine—Polyuria—Methotrexate—bone cancer	0.00173	0.0116	CcSEcCtD
Glycine—SLC16A10—tendon—bone cancer	0.00171	0.0111	CbGeAlD
Glycine—Coma—Doxorubicin—bone cancer	0.00166	0.0111	CcSEcCtD
Glycine—Thrombophlebitis—Epirubicin—bone cancer	0.00164	0.011	CcSEcCtD
Glycine—GPR18—GPCR downstream signaling—GRM4—bone cancer	0.00163	0.00235	CbGpPWpGaD
Glycine—GPR18—GPCR downstream signaling—RGS1—bone cancer	0.00163	0.00235	CbGpPWpGaD
Glycine—Visual disturbance—Methotrexate—bone cancer	0.0016	0.0107	CcSEcCtD
Glycine—GLRB—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.0016	0.00229	CbGpPWpGaD
Glycine—AGXT—Metabolism—NDUFA12—bone cancer	0.00158	0.00227	CbGpPWpGaD
Glycine—Vision blurred—Cisplatin—bone cancer	0.00157	0.0105	CcSEcCtD
Glycine—GARS—Gene Expression—NR1I2—bone cancer	0.00154	0.00221	CbGpPWpGaD
Glycine—GLYATL1—Metabolism—NT5C3A—bone cancer	0.00154	0.00221	CbGpPWpGaD
Glycine—GLYATL2—Metabolism—NT5C3A—bone cancer	0.00154	0.00221	CbGpPWpGaD
Glycine—GATM—Metabolism—NT5C3A—bone cancer	0.00154	0.00221	CbGpPWpGaD
Glycine—GLYAT—Metabolism—NT5C3A—bone cancer	0.00154	0.00221	CbGpPWpGaD
Glycine—ALAS1—Metabolism—NDUFA12—bone cancer	0.00153	0.0022	CbGpPWpGaD
Glycine—GSS—Biological oxidations—GSTP1—bone cancer	0.00153	0.00219	CbGpPWpGaD
Glycine—Thrombophlebitis—Doxorubicin—bone cancer	0.00152	0.0102	CcSEcCtD
Glycine—GSS—Metapathway biotransformation—GSTP1—bone cancer	0.0015	0.00216	CbGpPWpGaD
Glycine—GPR18—Signaling by GPCR—GRM4—bone cancer	0.00148	0.00213	CbGpPWpGaD
Glycine—GPR18—Signaling by GPCR—RGS1—bone cancer	0.00148	0.00213	CbGpPWpGaD
Glycine—BAAT—Metabolism—NT5C3A—bone cancer	0.00147	0.00211	CbGpPWpGaD
Glycine—GLRA1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.00146	0.0021	CbGpPWpGaD
Glycine—Convulsion—Cisplatin—bone cancer	0.00145	0.00967	CcSEcCtD
Glycine—SLC32A1—Transmission across Chemical Synapses—BRAF—bone cancer	0.00144	0.00207	CbGpPWpGaD
Glycine—Hyponatraemia—Epirubicin—bone cancer	0.00143	0.00956	CcSEcCtD
Glycine—GPR18—GPCR downstream signaling—GRM1—bone cancer	0.00142	0.00203	CbGpPWpGaD
Glycine—SHMT1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—bone cancer	0.0014	0.00201	CbGpPWpGaD
Glycine—Oedema—Cisplatin—bone cancer	0.00136	0.00911	CcSEcCtD
Glycine—AGXT2—Metabolism—NDUFA12—bone cancer	0.00135	0.00193	CbGpPWpGaD
Glycine—Tachycardia—Cisplatin—bone cancer	0.00133	0.00889	CcSEcCtD
Glycine—SHMT1—Validated targets of C-MYC transcriptional activation—MMP9—bone cancer	0.00133	0.0019	CbGpPWpGaD
Glycine—Dehydration—Epirubicin—bone cancer	0.00132	0.00885	CcSEcCtD
Glycine—Hyponatraemia—Doxorubicin—bone cancer	0.00132	0.00884	CcSEcCtD
Glycine—AGXT—Metabolism—NT5C3A—bone cancer	0.00131	0.00188	CbGpPWpGaD
Glycine—SLC36A1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.0013	0.00187	CbGpPWpGaD
Glycine—GPR18—Signaling by GPCR—GRM1—bone cancer	0.00129	0.00185	CbGpPWpGaD
Glycine—Hypotension—Cisplatin—bone cancer	0.00127	0.00851	CcSEcCtD
Glycine—ALAS1—Metabolism—NT5C3A—bone cancer	0.00127	0.00182	CbGpPWpGaD
Glycine—GLRA1—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.00126	0.00181	CbGpPWpGaD
Glycine—Dehydration—Doxorubicin—bone cancer	0.00122	0.00819	CcSEcCtD
Glycine—SLC32A1—Transmission across Chemical Synapses—MDM2—bone cancer	0.00121	0.00173	CbGpPWpGaD
Glycine—Angina pectoris—Epirubicin—bone cancer	0.0012	0.00801	CcSEcCtD
Glycine—Pain—Cisplatin—bone cancer	0.00116	0.00779	CcSEcCtD
Glycine—GARS—Gene Expression—EIF2S1—bone cancer	0.00114	0.00164	CbGpPWpGaD
Glycine—SLC36A1—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.00113	0.00162	CbGpPWpGaD
Glycine—AGXT2—Metabolism—NT5C3A—bone cancer	0.00112	0.0016	CbGpPWpGaD
Glycine—Angina pectoris—Doxorubicin—bone cancer	0.00111	0.00742	CcSEcCtD
Glycine—SLC32A1—Neuronal System—BRAF—bone cancer	0.0011	0.00158	CbGpPWpGaD
Glycine—SHMT1—Metabolism—NDUFA12—bone cancer	0.0011	0.00158	CbGpPWpGaD
Glycine—GSS—Metabolism—NDUFA12—bone cancer	0.00107	0.00153	CbGpPWpGaD
Glycine—SHMT1—Folate Metabolism—TP53—bone cancer	0.00104	0.00149	CbGpPWpGaD
Glycine—Visual impairment—Methotrexate—bone cancer	0.00101	0.00678	CcSEcCtD
Glycine—Hypersensitivity—Cisplatin—bone cancer	0.001	0.00671	CcSEcCtD
Glycine—GARS—Gene Expression—EZH2—bone cancer	0.00099	0.00142	CbGpPWpGaD
Glycine—Rhinitis—Epirubicin—bone cancer	0.000987	0.0066	CcSEcCtD
Glycine—Visual impairment—Epirubicin—bone cancer	0.000949	0.00635	CcSEcCtD
Glycine—Chills—Methotrexate—bone cancer	0.000944	0.00631	CcSEcCtD
Glycine—Diarrhoea—Cisplatin—bone cancer	0.000932	0.00623	CcSEcCtD
Glycine—GRIN2C—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000929	0.00133	CbGpPWpGaD
Glycine—SLC32A1—Neuronal System—MDM2—bone cancer	0.000925	0.00133	CbGpPWpGaD
Glycine—Rhinitis—Doxorubicin—bone cancer	0.000913	0.00611	CcSEcCtD
Glycine—GPR18—GPCR downstream signaling—GNA11—bone cancer	0.000913	0.00131	CbGpPWpGaD
Glycine—SHMT1—Metabolism—NT5C3A—bone cancer	0.000909	0.00131	CbGpPWpGaD
Glycine—GPR18—Signaling by GPCR—SMO—bone cancer	0.000907	0.0013	CbGpPWpGaD
Glycine—SHMT1—Validated targets of C-MYC transcriptional activation—TP53—bone cancer	0.000899	0.00129	CbGpPWpGaD
Glycine—ALAS2—Metabolism—ENO2—bone cancer	0.000891	0.00128	CbGpPWpGaD
Glycine—Back pain—Methotrexate—bone cancer	0.000886	0.00593	CcSEcCtD
Glycine—GSS—Metabolism—NT5C3A—bone cancer	0.000886	0.00127	CbGpPWpGaD
Glycine—Chills—Epirubicin—bone cancer	0.000883	0.00591	CcSEcCtD
Glycine—Visual impairment—Doxorubicin—bone cancer	0.000878	0.00587	CcSEcCtD
Glycine—GPR18—Signaling Pathways—GRM4—bone cancer	0.000877	0.00126	CbGpPWpGaD
Glycine—GPR18—Signaling Pathways—RGS1—bone cancer	0.000877	0.00126	CbGpPWpGaD
Glycine—Vomiting—Cisplatin—bone cancer	0.000866	0.00579	CcSEcCtD
Glycine—Vision blurred—Methotrexate—bone cancer	0.000863	0.00577	CcSEcCtD
Glycine—GPR18—Signaling by GPCR—GNA11—bone cancer	0.000829	0.00119	CbGpPWpGaD
Glycine—Back pain—Epirubicin—bone cancer	0.000829	0.00555	CcSEcCtD
Glycine—GPR18—GPCR downstream signaling—IL3—bone cancer	0.000828	0.00119	CbGpPWpGaD
Glycine—ALAS2—Metabolism—DHFR—bone cancer	0.000827	0.00119	CbGpPWpGaD
Glycine—Vertigo—Methotrexate—bone cancer	0.000823	0.0055	CcSEcCtD
Glycine—Chills—Doxorubicin—bone cancer	0.000817	0.00547	CcSEcCtD
Glycine—Nausea—Cisplatin—bone cancer	0.000809	0.00541	CcSEcCtD
Glycine—Vision blurred—Epirubicin—bone cancer	0.000808	0.0054	CcSEcCtD
Glycine—Convulsion—Methotrexate—bone cancer	0.000793	0.00531	CcSEcCtD
Glycine—SLC16A10—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000793	0.00114	CbGpPWpGaD
Glycine—GRIN2C—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000778	0.00112	CbGpPWpGaD
Glycine—ALAS2—Metabolism—GNA11—bone cancer	0.000773	0.00111	CbGpPWpGaD
Glycine—Vertigo—Epirubicin—bone cancer	0.00077	0.00515	CcSEcCtD
Glycine—Back pain—Doxorubicin—bone cancer	0.000767	0.00513	CcSEcCtD
Glycine—GPR18—Signaling Pathways—GRM1—bone cancer	0.00076	0.00109	CbGpPWpGaD
Glycine—GPR18—Signaling by GPCR—IL3—bone cancer	0.000752	0.00108	CbGpPWpGaD
Glycine—Vision blurred—Doxorubicin—bone cancer	0.000747	0.005	CcSEcCtD
Glycine—Convulsion—Epirubicin—bone cancer	0.000743	0.00497	CcSEcCtD
Glycine—Vertigo—Doxorubicin—bone cancer	0.000712	0.00477	CcSEcCtD
Glycine—GRIN2A—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000709	0.00102	CbGpPWpGaD
Glycine—GRIN2C—Alzheimers Disease—TP53—bone cancer	0.000706	0.00101	CbGpPWpGaD
Glycine—ALAS2—Metabolism—CYP3A4—bone cancer	0.000701	0.00101	CbGpPWpGaD
Glycine—Oedema—Epirubicin—bone cancer	0.000699	0.00468	CcSEcCtD
Glycine—Hypotension—Methotrexate—bone cancer	0.000698	0.00467	CcSEcCtD
Glycine—GRIN2C—Transmission across Chemical Synapses—BRAF—bone cancer	0.000698	0.001	CbGpPWpGaD
Glycine—Convulsion—Doxorubicin—bone cancer	0.000687	0.0046	CcSEcCtD
Glycine—SLC16A10—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000684	0.000983	CbGpPWpGaD
Glycine—Tachycardia—Epirubicin—bone cancer	0.000683	0.00457	CcSEcCtD
Glycine—GLYATL1—Metabolism—ENO2—bone cancer	0.000676	0.00097	CbGpPWpGaD
Glycine—GLYATL2—Metabolism—ENO2—bone cancer	0.000676	0.00097	CbGpPWpGaD
Glycine—GLYAT—Metabolism—ENO2—bone cancer	0.000676	0.00097	CbGpPWpGaD
Glycine—GATM—Metabolism—ENO2—bone cancer	0.000676	0.00097	CbGpPWpGaD
Glycine—Hypotension—Epirubicin—bone cancer	0.000654	0.00437	CcSEcCtD
Glycine—Oedema—Doxorubicin—bone cancer	0.000647	0.00433	CcSEcCtD
Glycine—BAAT—Metabolism—ENO2—bone cancer	0.000644	0.000925	CbGpPWpGaD
Glycine—Pain—Methotrexate—bone cancer	0.000639	0.00428	CcSEcCtD
Glycine—Tachycardia—Doxorubicin—bone cancer	0.000632	0.00423	CcSEcCtD
Glycine—GLYATL2—Metabolism—DHFR—bone cancer	0.000627	0.0009	CbGpPWpGaD
Glycine—GLYAT—Metabolism—DHFR—bone cancer	0.000627	0.0009	CbGpPWpGaD
Glycine—GATM—Metabolism—DHFR—bone cancer	0.000627	0.0009	CbGpPWpGaD
Glycine—GLYATL1—Metabolism—DHFR—bone cancer	0.000627	0.0009	CbGpPWpGaD
Glycine—Hypotension—Doxorubicin—bone cancer	0.000605	0.00405	CcSEcCtD
Glycine—ALAS2—Metabolism—GSTP1—bone cancer	0.000599	0.000861	CbGpPWpGaD
Glycine—Pain—Epirubicin—bone cancer	0.000598	0.004	CcSEcCtD
Glycine—BAAT—Metabolism—DHFR—bone cancer	0.000598	0.000858	CbGpPWpGaD
Glycine—GRIN2A—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000594	0.000853	CbGpPWpGaD
Glycine—Urticaria—Methotrexate—bone cancer	0.000594	0.00397	CcSEcCtD
Glycine—GLYATL2—Metabolism—GNA11—bone cancer	0.000586	0.000841	CbGpPWpGaD
Glycine—GLYAT—Metabolism—GNA11—bone cancer	0.000586	0.000841	CbGpPWpGaD
Glycine—GATM—Metabolism—GNA11—bone cancer	0.000586	0.000841	CbGpPWpGaD
Glycine—GLYATL1—Metabolism—GNA11—bone cancer	0.000586	0.000841	CbGpPWpGaD
Glycine—GRIN2C—Transmission across Chemical Synapses—MDM2—bone cancer	0.000585	0.00084	CbGpPWpGaD
Glycine—AGXT—Metabolism—ENO2—bone cancer	0.000574	0.000825	CbGpPWpGaD
Glycine—BAAT—Metabolism—GNA11—bone cancer	0.000559	0.000802	CbGpPWpGaD
Glycine—ALAS1—Metabolism—ENO2—bone cancer	0.000556	0.000799	CbGpPWpGaD
Glycine—Urticaria—Epirubicin—bone cancer	0.000556	0.00372	CcSEcCtD
Glycine—Pain—Doxorubicin—bone cancer	0.000553	0.0037	CcSEcCtD
Glycine—Hypersensitivity—Methotrexate—bone cancer	0.000551	0.00368	CcSEcCtD
Glycine—GRIN2A—Alzheimers Disease—TP53—bone cancer	0.000539	0.000774	CbGpPWpGaD
Glycine—GPR18—Signaling Pathways—SMO—bone cancer	0.000536	0.000769	CbGpPWpGaD
Glycine—GRIN2C—Neuronal System—BRAF—bone cancer	0.000535	0.000768	CbGpPWpGaD
Glycine—GRIN2A—Transmission across Chemical Synapses—BRAF—bone cancer	0.000533	0.000765	CbGpPWpGaD
Glycine—AGXT—Metabolism—DHFR—bone cancer	0.000533	0.000765	CbGpPWpGaD
Glycine—GLYAT—Metabolism—CYP3A4—bone cancer	0.000531	0.000762	CbGpPWpGaD
Glycine—GATM—Metabolism—CYP3A4—bone cancer	0.000531	0.000762	CbGpPWpGaD
Glycine—GLYATL2—Metabolism—CYP3A4—bone cancer	0.000531	0.000762	CbGpPWpGaD
Glycine—GLYATL1—Metabolism—CYP3A4—bone cancer	0.000531	0.000762	CbGpPWpGaD
Glycine—ALAS1—Metabolism—DHFR—bone cancer	0.000516	0.000741	CbGpPWpGaD
Glycine—Hypersensitivity—Epirubicin—bone cancer	0.000515	0.00345	CcSEcCtD
Glycine—Urticaria—Doxorubicin—bone cancer	0.000514	0.00344	CcSEcCtD
Glycine—Diarrhoea—Methotrexate—bone cancer	0.000511	0.00342	CcSEcCtD
Glycine—BAAT—Metabolism—CYP3A4—bone cancer	0.000507	0.000727	CbGpPWpGaD
Glycine—BAAT—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	0.000504	0.000724	CbGpPWpGaD
Glycine—AGXT—Metabolism—GNA11—bone cancer	0.000498	0.000715	CbGpPWpGaD
Glycine—Dizziness—Methotrexate—bone cancer	0.000494	0.00331	CcSEcCtD
Glycine—GPR18—Signaling Pathways—GNA11—bone cancer	0.00049	0.000703	CbGpPWpGaD
Glycine—AGXT2—Metabolism—ENO2—bone cancer	0.000488	0.000701	CbGpPWpGaD
Glycine—ALAS1—Metabolism—GNA11—bone cancer	0.000482	0.000693	CbGpPWpGaD
Glycine—Diarrhoea—Epirubicin—bone cancer	0.000479	0.0032	CcSEcCtD
Glycine—Hypersensitivity—Doxorubicin—bone cancer	0.000477	0.00319	CcSEcCtD
Glycine—SHMT1—Disease—ENO2—bone cancer	0.000475	0.000683	CbGpPWpGaD
Glycine—Vomiting—Methotrexate—bone cancer	0.000475	0.00318	CcSEcCtD
Glycine—Dizziness—Epirubicin—bone cancer	0.000463	0.00309	CcSEcCtD
Glycine—GPR18—Signaling Pathways—ATF1—bone cancer	0.000455	0.000654	CbGpPWpGaD
Glycine—GLYATL1—Metabolism—GSTP1—bone cancer	0.000454	0.000652	CbGpPWpGaD
Glycine—GLYATL2—Metabolism—GSTP1—bone cancer	0.000454	0.000652	CbGpPWpGaD
Glycine—GLYAT—Metabolism—GSTP1—bone cancer	0.000454	0.000652	CbGpPWpGaD
Glycine—GATM—Metabolism—GSTP1—bone cancer	0.000454	0.000652	CbGpPWpGaD
Glycine—AGXT2—Metabolism—DHFR—bone cancer	0.000453	0.000651	CbGpPWpGaD
Glycine—AGXT—Metabolism—CYP3A4—bone cancer	0.000452	0.000648	CbGpPWpGaD
Glycine—GRIN2C—Neuronal System—MDM2—bone cancer	0.000448	0.000644	CbGpPWpGaD
Glycine—GRIN2A—Transmission across Chemical Synapses—MDM2—bone cancer	0.000447	0.000641	CbGpPWpGaD
Glycine—Vomiting—Epirubicin—bone cancer	0.000445	0.00297	CcSEcCtD
Glycine—GPR18—Signaling Pathways—IL3—bone cancer	0.000444	0.000638	CbGpPWpGaD
Glycine—Nausea—Methotrexate—bone cancer	0.000444	0.00297	CcSEcCtD
Glycine—Diarrhoea—Doxorubicin—bone cancer	0.000443	0.00296	CcSEcCtD
Glycine—SHMT1—Disease—DHFR—bone cancer	0.000441	0.000633	CbGpPWpGaD
Glycine—ALAS1—Metabolism—CYP3A4—bone cancer	0.000437	0.000628	CbGpPWpGaD
Glycine—ALAS1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	0.000435	0.000625	CbGpPWpGaD
Glycine—BAAT—Metabolism—GSTP1—bone cancer	0.000433	0.000622	CbGpPWpGaD
Glycine—Dizziness—Doxorubicin—bone cancer	0.000428	0.00286	CcSEcCtD
Glycine—AGXT2—Metabolism—GNA11—bone cancer	0.000423	0.000608	CbGpPWpGaD
Glycine—Nausea—Epirubicin—bone cancer	0.000415	0.00278	CcSEcCtD
Glycine—Vomiting—Doxorubicin—bone cancer	0.000411	0.00275	CcSEcCtD
Glycine—GRIN2A—Neuronal System—BRAF—bone cancer	0.000408	0.000586	CbGpPWpGaD
Glycine—SHMT1—Metabolism—ENO2—bone cancer	0.000398	0.000572	CbGpPWpGaD
Glycine—GSS—Metabolism—ENO2—bone cancer	0.000388	0.000557	CbGpPWpGaD
Glycine—AGXT—Metabolism—GSTP1—bone cancer	0.000386	0.000555	CbGpPWpGaD
Glycine—Nausea—Doxorubicin—bone cancer	0.000384	0.00257	CcSEcCtD
Glycine—AGXT2—Metabolism—CYP3A4—bone cancer	0.000384	0.000551	CbGpPWpGaD
Glycine—GPR18—Signaling Pathways—TGFBR2—bone cancer	0.00038	0.000545	CbGpPWpGaD
Glycine—ALAS1—Metabolism—GSTP1—bone cancer	0.000374	0.000537	CbGpPWpGaD
Glycine—SHMT1—Metabolism—DHFR—bone cancer	0.000369	0.00053	CbGpPWpGaD
Glycine—GSS—Metabolism—DHFR—bone cancer	0.00036	0.000517	CbGpPWpGaD
Glycine—GPR18—Signaling Pathways—IGF1R—bone cancer	0.000357	0.000513	CbGpPWpGaD
Glycine—SHMT1—Metabolism—GNA11—bone cancer	0.000345	0.000496	CbGpPWpGaD
Glycine—GRIN2A—Neuronal System—MDM2—bone cancer	0.000342	0.000491	CbGpPWpGaD
Glycine—GSS—Metabolism—GNA11—bone cancer	0.000336	0.000483	CbGpPWpGaD
Glycine—AGXT2—Metabolism—GSTP1—bone cancer	0.000328	0.000471	CbGpPWpGaD
Glycine—SHMT1—Disease—TGFBR2—bone cancer	0.00032	0.000459	CbGpPWpGaD
Glycine—SHMT1—Metabolism—CYP3A4—bone cancer	0.000313	0.000449	CbGpPWpGaD
Glycine—ALAS2—Metabolism—PTGS2—bone cancer	0.00031	0.000446	CbGpPWpGaD
Glycine—GSS—Metabolism—CYP3A4—bone cancer	0.000305	0.000438	CbGpPWpGaD
Glycine—SHMT1—Metabolism—GSTP1—bone cancer	0.000268	0.000384	CbGpPWpGaD
Glycine—GSS—Metabolism—GSTP1—bone cancer	0.000261	0.000375	CbGpPWpGaD
Glycine—GPR18—Signaling Pathways—KIT—bone cancer	0.000259	0.000372	CbGpPWpGaD
Glycine—GPR18—Signaling Pathways—BRAF—bone cancer	0.000244	0.00035	CbGpPWpGaD
Glycine—GPR18—Signaling by GPCR—EGFR—bone cancer	0.000236	0.000339	CbGpPWpGaD
Glycine—GLYATL1—Metabolism—PTGS2—bone cancer	0.000235	0.000338	CbGpPWpGaD
Glycine—GLYAT—Metabolism—PTGS2—bone cancer	0.000235	0.000338	CbGpPWpGaD
Glycine—GLYATL2—Metabolism—PTGS2—bone cancer	0.000235	0.000338	CbGpPWpGaD
Glycine—GATM—Metabolism—PTGS2—bone cancer	0.000235	0.000338	CbGpPWpGaD
Glycine—BAAT—Metabolism—PTGS2—bone cancer	0.000224	0.000322	CbGpPWpGaD
Glycine—SHMT1—Disease—KIT—bone cancer	0.000218	0.000313	CbGpPWpGaD
Glycine—SHMT1—Disease—BRAF—bone cancer	0.000205	0.000294	CbGpPWpGaD
Glycine—GPR18—Signaling Pathways—MDM2—bone cancer	0.000204	0.000293	CbGpPWpGaD
Glycine—AGXT—Metabolism—PTGS2—bone cancer	0.0002	0.000287	CbGpPWpGaD
Glycine—ALAS1—Metabolism—PTGS2—bone cancer	0.000194	0.000278	CbGpPWpGaD
Glycine—GPR18—Signaling Pathways—JUN—bone cancer	0.000177	0.000255	CbGpPWpGaD
Glycine—GPR18—Signaling Pathways—MMP9—bone cancer	0.000173	0.000248	CbGpPWpGaD
Glycine—SHMT1—Disease—MDM2—bone cancer	0.000172	0.000247	CbGpPWpGaD
Glycine—AGXT2—Metabolism—PTGS2—bone cancer	0.00017	0.000244	CbGpPWpGaD
Glycine—SHMT1—Disease—PTGS2—bone cancer	0.000166	0.000238	CbGpPWpGaD
Glycine—GPR18—Signaling Pathways—EGFR—bone cancer	0.000139	0.0002	CbGpPWpGaD
Glycine—SHMT1—Metabolism—PTGS2—bone cancer	0.000139	0.000199	CbGpPWpGaD
Glycine—GSS—Metabolism—PTGS2—bone cancer	0.000135	0.000194	CbGpPWpGaD
Glycine—SHMT1—Disease—EGFR—bone cancer	0.000117	0.000169	CbGpPWpGaD
Glycine—GPR18—Signaling Pathways—TP53—bone cancer	0.000117	0.000168	CbGpPWpGaD
